Skip to main content

Table 5 Combined effects of metabolic syndrome and VEGF 3′-UTR variants on colon cancer and rectal cancer risks

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

  CC risk RC risk
  Without MetS With MetS Without MetS With MetS
Genotype AOR (95% CI) p AOR (95% CI) p AOR (95% CI) p AOR (95% CI) p
VEGF 1451CC 1.00 (reference)   2.17 (1.43 - 3.28) <.001 1.00 (reference)   2.22 (1.38 - 3.57) 0.001
VEGF 1451CT+TT 1.18 (0.79 - 1.77) 0.416 1.76 (0.98 - 3.16) 0.060 1.67 (1.07 - 2.61) 0.023 3.15 (1.74 - 5.70) <.001
VEGF 1612GG 1.00 (reference)   1.68 (1.12 - 2.53) 0.013 1.00 (reference)   1.94 (1.24 - 3.01) 0.003
VEGF 1612GA+AA 0.71 (0.46 - 1.09) 0.117 1.81 (1.03 - 3.19) 0.040 0.69 (0.42 - 1.14) 0.148 1.66 (0.88 - 3.15) 0.117
VEGF 1725GG 1.00 (reference)   1.88 (1.29 - 2.73) 0.001 1.00 (reference)   2.17 (1.44 - 3.27) <.001
VEGF 1725GA+AA 1.34 (0.72 - 2.49) 0.360 2.68 (1.30 - 5.55) 0.008 1.82 (0.95 - 3.48) 0.072 2.49 (1.11 - 5.57) 0.027
  1. Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and p values were adjusted by age and gender.